CAR T-cell Therapy | Specialty

The car t-cell therapy condition center is a comprehensive resource for clinical news and expert insights on car t-cell therapy. Read more at OncLive.

Five Under 5: Top Oncology Videos for the Week of 3/30

April 6th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, ovarian cancer, prostate cancer, breast cancer, and follicular lymphoma.

The OncFive: Top Oncology Articles for the Week of 3/30

April 5th 2025

Orca-T boosts cGVHD-free survival in hematologic malignancies, cilta-cel continues to impress in CARTITUDE-4, and more.

FELIX Analysis Suggests Consolidative SCT After Obe-Cel Does Not Improve EFS/OS in R/R B-ALL

April 4th 2025

A small sample size from an analysis of the FELIX trial suggests consolidative SCT may not be needed after obe-cel treatment in relapsed/refractory B-ALL.

Dr Farid on the Efficacy of MDC-CAR-BCMA001 in R/R Myeloma and AL Amyloidosis

April 3rd 2025

Kiavasch Mohammad Nejad Farid, MD, discusses the efficacy of MDC-CAR-BCMA001 in relapsed/refractory multiple myeloma and systemic light chain (AL) amyloidosis.

Single-Center Experience Highlights Utility of CD19-Directed CAR T-Cell Therapy in B-Cell Malignancies

April 3rd 2025

Real-world data with axi-cel, tisa-cel, and brexu-cel in patients with B-cell malignancies proved comparable to other experiences with cellular therapy.

Dr Davila on the Future Use of Biomarkers to Predict CAR T-Cell Therapy Resistance in LBCL

April 3rd 2025

Marco Davila, MD, PhD, discusses how a study of tumor drivers of CAR T-cell therapy resistance in LBCL may promote future biomarker investigations.

Axi-Cel Is Associated With Higher ORR, Increased CRS/ICANS vs Tisa-cel in Older Patients With R/R DLBCL

April 2nd 2025

Axi-cel led to higher response rates but increased toxicity vs tisa-cel in older patients with relapsed/refractory DLBCL.

Brexu-Cel Demonstrates Efficacy, Safety in Older Patients with R/R Mantle Cell Lymphoma

April 2nd 2025

Brexu-cel demonstrated clinical activity and safety in patients over 70 years of age with relapsed/refractory mantle cell lymphoma.

Cilta-Cel Significantly Boosts MRD Negativity Rates in Lenalidomide-Refractory Myeloma

April 1st 2025

Cilta-cel improved rates of MRD negativity and 30-month PFS vs SOC in patients with lenalidomide-refractory multiple myeloma with MRD negativity.

Inotuzumab Ozogamicin–Based Bridging Therapy Boosts Obe-Cel Outcomes in B-Cell ALL

April 1st 2025

The addition of inotuzumab ozogamicin to bridging therapy led to high objective response rates and sustained survival in obe-cel recipients with B-cell ALL.

Donor-Derived CAR T-Cell Therapy Yields High CR Rate With Limited OS in T-Cell Lymphoma After Allo-HSCT Relapse

April 1st 2025

A donor-derived CAR T-cell therapy produced complete remissions, but survival was limited in relapsed/refractory T-cell lymphoma.

Dr Oluwole on AE Mitigation Following Axi-Cel in R/R LBCL

March 31st 2025

Olalekan O. Oluwole, MD, MPH, details the importance of early intervention regarding adverse effects following CAR T products in relapsed/refractory LBCL.

Optimized Tandem CD19/CD20–Directed CAR T Plus ASCT Elicits Durable Responses in R/R B-Cell Lymphomas

March 31st 2025

Higher CR rates were achieved with the tandem CAR T-cell infusion plus ASCT vs the infusion alone in patients with relapsed/refractory B-cell lymphoma.

Effective Bridging Therapy Correlates With Improved PFS After Cilta-Cel in Multiple Myeloma

March 31st 2025

Improved PFS was associated with at least a 25% reduction in tumor burden before treatment with cilta-cel in patients with relapsed/refractory multiple myeloma.

Five Under 5: Top Oncology Videos for the Week of 3/23

March 30th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, HER2+ breast cancer, non¬–muscle-invasive bladder cancer, and ovarian cancer.

Dr Dholaria on Future Research Directions With P-BCMA-ALLO1 in R/R Multiple Myeloma

March 28th 2025

Bhagirathbhai Dholaria, MBBS, discusses future directions for research with P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma.

Blinatumomab Consolidation Prevents B-ALL Relapses and CAR T-Cell Therapy Consolidation May, Too

March 26th 2025

Gregory Roloff, MD, details data on consolidation therapy with blinatumomab or CAR T-cell therapy for B-ALL, and the role of these agents in this setting.

CAR T-Cell Therapy Shows Consistent Efficacy Across Age Groups in R/R LBCL

March 25th 2025

Median PFS and OS were comparable between age groups when CAR T-cell therapy was given as treatment for patients with relapsed/refractory LBCL.

Low Rates of Late-Onset CAR T-Cell–Related CRS/ICANS Support Shorter AE Monitoring Periods

March 25th 2025

Olalekan O. Oluwole, MD, discusses research findings showing that patients with LBCL may not need prolonged hospital monitoring following axi-cel infusion.

Dr Ali on Choosing Between CAR T-Cell Therapy and Bispecific Antibodies in R/R Multiple Myeloma

March 24th 2025

Syed Abbas Ali, MBBS, discusses treatment decisions for patients with R/R myeloma for whom CAR T-cell therapy and bispecific antibodies are both options.